News: Precision Cancer Medicine

Precision oncology expert Dr. Ben Ho Park sheds light on cancer treatment innovations.

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.

GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.

Precision radiation therapy helped treat patient Imogene Stranch’s cancer.

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

A group of young lung cancer patients and their family members recently toured research laboratories to learn how investigators are working to find better therapies and possibly a cure for the disease.

Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. He will assume his new post Sept. 1.

Vanderbilt researchers have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

Consuelo Wilkins, MD, MSCI, has been appointed director of a new Engagement Core to support the design, implementation and governance of the national All of Us Research Program, an ambitious effort led by the National Institutes of Health (NIH) to accelerate the prevention and treatment of illness through precision medicine.

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.